Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00209352 · ClinicalTrials.gov registry record · Phase 3
Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant
A Phase 3 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00209352 is a Phase 3 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 120 participants.
The verdict
NCT00209352, a Phase 3 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.
Interventions
- DRUG Acyclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1985-06 |
| Est. Completion | 2004-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00209352
The ClinicalTrials.gov registry entry for NCT00209352 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acyclovir is the first listed.
NCT00209352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00209352 about?
NCT00209352 is a clinical study titled "Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant". The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.
What is the current status of trial NCT00209352?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 1985-06. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00209352?
The interventions under investigation include: Acyclovir (DRUG).
Who is sponsoring clinical trial NCT00209352?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.